Leo Rasche, MD, University of Würzburg, Würzburg, Germany, briefly discusses novel emerging targets in multiple myeloma, including SLAMF7 and FcRH5, and further comments on the importance of combining agents. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.